Figure 11.

Co-targeting HER-2 and IGF-1R suppresses invasiveness of trastuzumab-resistant breast cancer cells. (A and B) JIMT-1 cells were pretreated for 48 h with the indicated inhibitors before being seeded in Boyden matrigel-coated chambers with 10% FBS. After 24 h, invasion was measured by taking photos and counting the number of invaded cells in 10 random fields; results represent the average of triplicates per group. Representative photos (A) and quantitation of the invasive cells under the different treatment conditions (B). (C and D) Similar inhibition of invasive capabilities of JIMT-1 cells were observed via co-targeting HER-1 and IGF-1R. Boyden chamber migration and invasion assay was performed as described above; photographs (C) and quantitative results of invasive cell number are shown in (D). Results are an average of 2 different experiments and error bars represent the mean ± S.D.. Statistical analysis demonstrated that combination treatment with HER-2 and the IGF-1R vaccine antibodies or HER-1 and IGF-1R vaccine antibodies significantly (p < 0.05) inhibited invasion.